Summary

Eligibility
for people ages 12 months to 21 years (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around

Description

Summary

This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a genetic alteration (mutation) in a signaling pathway called MAPK. A signaling pathway consists of a group of molecules in a cell that control one or more cell functions. Genes in the MAPK pathway are frequently mutated in many types of cancers. Ulixertinib may stop the growth of cancer cells that have mutations in the MAPK pathway.

Official Title

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Details

Keywords

Eligibility

Locations

  • Mattel Children's Hospital UCLA
    Los Angeles California 90095 United States
  • Children's Hospital Los Angeles
    Los Angeles California 90027 United States
  • Kaiser Permanente Downey Medical Center
    Downey California 90242 United States
  • Miller Children's and Women's Hospital Long Beach
    Long Beach California 90806 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT03698994
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 20 people participating
Last Updated